ProShare Advisors’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $68.1K | Sell |
18,912
-1,602
| -8% | -$5.77K | ﹤0.01% | 1947 |
|
|
2025
Q1 | $61.3K | Sell |
20,514
-5,219
| -20% | -$15.6K | ﹤0.01% | 1925 |
|
|
2024
Q4 | $86.2K | Buy |
25,733
+6,163
| +31% | +$20.6K | ﹤0.01% | 2099 |
|
|
2024
Q3 | $65.6K | Buy |
19,570
+4,104
| +27% | +$13.7K | ﹤0.01% | 1946 |
|
|
2024
Q2 | $51.2K | Sell |
15,466
-4,205
| -21% | -$13.9K | ﹤0.01% | 1746 |
|
|
2024
Q1 | $79.5K | Buy |
19,671
+1,651
| +9% | +$6.67K | ﹤0.01% | 1856 |
|
|
2023
Q4 | $55K | Buy |
18,020
+2,609
| +17% | +$7.96K | ﹤0.01% | 1850 |
|
|
2023
Q3 | $46.2K | Buy |
15,411
+45
| +0.3% | +$135 | ﹤0.01% | 1723 |
|
|
2023
Q2 | $57.5K | Buy |
15,366
+607
| +4% | +$2.27K | ﹤0.01% | 1757 |
|
|
2023
Q1 | $49.4K | Sell |
14,759
-1,948
| -12% | -$6.53K | ﹤0.01% | 1672 |
|
|
2022
Q4 | $80.4K | Buy |
16,707
+1,291
| +8% | +$6.21K | ﹤0.01% | 1689 |
|
|
2022
Q3 | $88K | Buy |
15,416
+361
| +2% | +$2.06K | ﹤0.01% | 1586 |
|
|
2022
Q2 | $108K | Sell |
15,055
-5,666
| -27% | -$40.6K | ﹤0.01% | 1602 |
|
|
2022
Q1 | $150K | Sell |
20,721
-5,104
| -20% | -$36.9K | ﹤0.01% | 1953 |
|
|
2021
Q4 | $231K | Buy |
25,825
+17,551
| +212% | +$157K | ﹤0.01% | 1944 |
|
|
2021
Q3 | $290K | Sell |
8,274
-8,929
| -52% | -$313K | ﹤0.01% | 1579 |
|
|
2021
Q2 | $370K | Buy |
17,203
+13,097
| +319% | +$282K | ﹤0.01% | 1745 |
|
|
2021
Q1 | $254K | Buy |
+4,106
| New | +$254K | ﹤0.01% | 1895 |
|